Genenta Science SPA
NASDAQ:GNTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Solaredge Technologies Inc
NASDAQ:SEDG
|
IL |
Genenta Science SPA
PP&E Net
Genenta Science SPA
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genenta Science SPA
NASDAQ:GNTA
|
PP&E Net
€42.9k
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Philogen SpA
MIL:PHIL
|
PP&E Net
€24.9m
|
CAGR 3-Years
6%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Ulisse Biomed Spa
MIL:UBM
|
PP&E Net
€2.2m
|
CAGR 3-Years
213%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
Genenta Science SPA
Glance View
Genenta Science SpA engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. The company is headquartered in Milan, Milano and currently employs 4 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
See Also
What is Genenta Science SPA's PP&E Net?
PP&E Net
42.9k
EUR
Based on the financial report for Dec 31, 2024, Genenta Science SPA's PP&E Net amounts to 42.9k EUR.
What is Genenta Science SPA's PP&E Net growth rate?
PP&E Net CAGR 3Y
29%
Over the last year, the PP&E Net growth was -48%. The average annual PP&E Net growth rates for Genenta Science SPA have been 29% over the past three years .
